Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

NextRNA launches to develop noncoding RNAs

by Michael McCoy
March 6, 2022 | A version of this story appeared in Volume 100, Issue 9

 

NextRNA Therapeutics has launched with $9.3 million in seed financing and a $46.8 million series A investment by several venture capital firms. The Cambridge, Massachusetts–based company is based on the work of Carl Novina at Dana-Farber Cancer Institute. It is focused on noncoding RNAs, which don’t make proteins but instead interact with and modulate the activity of proteins. NextRNA is developing two small molecules that target long noncoding RNAs that it says play roles in cancer and immunological conditions.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.